On March 13th, RudaCure and Hanlim Pharmaceutical held an advisory meeting for essais cliniques de Phase 2 of their traitement de la sécheresse oculaire, inviting 13 ophthalmology clinical experts.
At the advisory meeting held at the Mondrian Hotel, with the assistance of Hanlim Pharmaceutical's marketing department, 13 anterior segment ophthalmology professors from across the country were invited to share project descriptions and essai clinique de Phase 1 progress for RCI001/HL262, and to receive advice for avec succès conducting essais cliniques de Phase 2.
Nous remercions sincèrement tous les professeurs et Hanlim Pharmaceutical colleagues who attended, and nous ferons de notre mieux pour atteindre des résultats à la hauteur des attentes de chacun.